(Q47613523)

4 February 2018

title

Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy (English)

1 reference

4 February 2018

0 references

1 reference

1 reference

Hilal Eser Ozturk

1

0 references

author name string

Merih Oray

series ordinal

2

1 reference

4 February 2018

Ilknur Tugal-Tutkun

series ordinal

3

1 reference

4 February 2018

publication date

11 October 2017

1 reference

4 February 2018

Ocular Immunology and Inflammation

published in

1 reference

4 February 2018

page(s)

1-10

1 reference

4 February 2018

Differential diagnosis of behçet uveitis

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Uveitis in Behçet disease: an analysis of 880 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Therapy of ocular Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Tocilizumab treatment for refractory uveitis-related cystoid macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

IL-6: regulator of Treg/Th17 balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Elevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Tocilizumab in Uveitic Macular Edema Refractory to Previous Immunomodulatory Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

QUANTITATIVE ANALYSIS OF STRUCTURAL ALTERATIONS IN THE CHOROID OF PATIENTS WITH ACTIVE BEHÇET UVEITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

CSF levels of cytokines in neuro-Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

Anakinra treatment in drug-resistant Behcet’s disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1355471

10.1080/09273948.2017.1355471

21 January 2018

Identifiers

DOI

1 reference

4 February 2018

PubMed ID

29020500

1 reference

4 February 2018